Tarao K, Shimizu A, Harada M, Kuni Y, Ito Y, Tamai S, Iimori K, Sugimasa Y, Takemiya S, Okamoto T
Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan.
Cancer. 1989 Jul 1;64(1):104-9. doi: 10.1002/1097-0142(19890701)64:1<104::aid-cncr2820640119>3.0.co;2-5.
With the aim of examining increasing deoxyribonucleic acid (DNA) synthesis of liver cirrhotic tissue when hepatocellular carcinoma (HCC) is developing, bromodeoxyuridine labeling indices (BrdU LI) of liver biopsy specimens from 19 control cirrhotic (control LC) patients without HCC, 19 cirrhotic patients with HCC, and from six control subjects were examined using an in vitro labeling technique. The mean BrdU LI +/- SD of HCC cancerous portion, HCC non-cancerous cirrhotic portion, control LC, and of control subjects were 7.2 +/- 2.9%, 3.3 +/- 1.5%, 2.1 +/- 1.7%, and 0.25 +/- 0.09%, respectively. Interesting enough, there was a significant difference (P less than 0.05) between the non-cancerous cirrhotic portion and control LC. Although all 17 non-cancerous cirrhotic portion belonged to the high LI group (greater than or equal to 1.5%), 10 of 19 in the control LC belonged to the low LI group (less than 1.5%) (P less than 0.001). The authors conclude that HCC would develop in the cirrhotics with high DNA synthetic potency.
为了研究肝细胞癌（HCC）发生时肝硬化组织中脱氧核糖核酸（DNA）合成增加的情况，采用体外标记技术检测了19例无HCC的对照肝硬化（对照LC）患者、19例伴有HCC的肝硬化患者以及6例对照受试者肝活检标本的溴脱氧尿苷标记指数（BrdU LI）。HCC癌组织部分、HCC非癌性肝硬化部分、对照LC以及对照受试者的平均BrdU LI±标准差分别为7.2±2.9%、3.3±1.5%、2.1±1.7%和0.25±0.09%。有趣的是，非癌性肝硬化部分与对照LC之间存在显著差异（P<0.05）。虽然所有17个非癌性肝硬化部分都属于高LI组（≥1.5%），但对照LC组19例中有10例属于低LI组（<1.5%）（P<0.001）。作者得出结论，DNA合成能力高的肝硬化患者会发生HCC。
Zotero 插件